Respiratory syncytial virus (RSV) is a common, highly contagious illness that affects the nose, throat, and lungs. Although RSV usually causes mild illness with cold-like symptoms, the infection can ...

New real-world data suggests that seniors who get the RSV vaccine have an 80% lower odds for severe illness It's yet another reason to get immunized ahead of another RSV season Widespread immunization ...

RSV is a virus that can make people sick, especially older adults and babies. But even though RSV can be serious, people aren't as worried about it anymore. RSV is common but can be dangerous ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...

Today, we talk about some RSV competition that’s brewing, how Alnylam’s CEO spoke about its plans with ATTR-CM, and more. Alnylam Pharmaceuticals is expanding the footprint of its RNA-based ...

Timely diagnosis of RSV is imperative for optimal patient management; by rapidly identifying RSV infection, health professionals can implement appropriate infection control measures while limiting ...

Sanofi is trailing behind GSK and Pfizer when it comes to vaccines for respiratory syncytial virus (RSV), but it still thinks it can be the top player in the market with a combination of its ...

Cold and flu season — otherwise known as mid-October — is upon us. But this year, several advancements in vaccines could help families keep viruses at bay. One of the new developments is a ...

Respiratory syncytial (sin-SISH-uhl) virus, or RSV, is a common virus that infects the nose, throat and lungs. RSV starts to circulate in the fall and winter months and continues to early spring. Most ...